Consequently, CDK9 antagonism, by impairing rRNA processing, rapidly culminates in nucleolar stress, and the subsequent termination of RiBi, providing a novel MCL-1 independent mechanism by which CDK9 antagonism is a therapeutic vulnerability in GATA-3 dependent T-cell lymphomas. This evidence concerns the gene CDK9 and T-cell non-Hodgkin lymphoma.